---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-10T23:07:52.192213'
end_time: '2026-02-10T23:16:29.777739'
duration_seconds: 517.59
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Lipoyl Transferase 1 Deficiency
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 16
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Lipoyl Transferase 1 Deficiency
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Lipoyl Transferase 1 Deficiency**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Lipoyl Transferase 1 Deficiency
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Lipoyl Transferase 1 Deficiency**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Plan
- Objective 1 (literature retrieval): Completed using recent mechanistic papers and a foundational review (2023–2024 priority; 2021 review for pathway context) (dreishpoon2023fdx1regulatescellular pages 1-2, bick2024engineeredbacteriallipoate pages 4-5, kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47, bick2024engineeredbacteriallipoate pages 2-3).
- Objective 2 (core pathophysiology extraction): Completed below with pathway steps, affected enzyme complexes, and cellular processes, citing primary sources (dreishpoon2023fdx1regulatescellular pages 1-2, bick2024engineeredbacteriallipoate pages 2-3, bick2024engineeredbacteriallipoate pages 4-5).
- Objective 3 (key molecular players and anatomical/cellular context): Completed below, structured for ontology annotation (HGNC/GO/HP/CL/UBERON/CHEBI) (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Objective 4 (biological processes and cellular components): Completed below (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Objective 5 (disease progression and phenotypes with statistics): Completed to the extent supported by available evidence; note that robust cohort statistics for LIPT1 deficiency remain limited in accessible sources; we summarize phenotypes reported across cases (bick2024engineeredbacteriallipoate pages 5-6, kastaniotis2021mitochondrialfattyacids pages 37-42).
- Objective 6 (evidence artifact): Created and will embed for transparent sourcing (artifact-00) (bick2024engineeredbacteriallipoate pages 4-5, dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 32-37).
- Objective 7 (final comprehensive report): Delivered below with citations and URLs.

Disease Pathophysiology Research Report

Target Disease
- Disease Name: Lipoyl Transferase 1 Deficiency (LIPT1 deficiency)
- MONDO ID: not reliably identified in the accessible sources; LIPT1 deficiency is recognized among human disorders of mitochondrial protein lipoylation.
- Category: Mendelian

1) Core Pathophysiology
- Primary mechanistic defect: loss or reduction of mitochondrial protein lipoylation on the E2 subunits (dihydrolipoyl acyltransferases) of four multienzyme complexes: pyruvate dehydrogenase (PDH; E2=DLAT), α-ketoglutarate dehydrogenase/OGDH (E2=DLST), branched-chain α‑ketoacid dehydrogenase/BCKDH (E2=DBT), and glycine cleavage system (GCS; H protein=GCSH). Disruption of lipoylation leads to loss of activity of these complexes and impaired cellular respiration with glucose-dependence phenotypes (e.g., growth failure in low glucose) (URL: https://doi.org/10.1016/j.jbc.2023.105046; https://doi.org/10.1016/j.jbc.2024.107995) (dreishpoon2023fdx1regulatescellular pages 1-2, bick2024engineeredbacteriallipoate pages 2-3, bick2024engineeredbacteriallipoate pages 4-5).
- Lipoylation pathway steps: mitochondrial fatty acid synthesis (mtFAS) generates octanoyl-ACP; LIPT2 transfers octanoyl to GCSH; LIAS (radical SAM enzyme, Fe–S cluster dependent, supported by FDX1) inserts sulfur atoms to generate lipoyl-GCSH; LIPT1 transfers the lipoyl moiety from GCSH to E2 lysine residues on PDH/OGDH/BCKDH and to the H protein as needed. This establishes the linear dependency mtFAS → LIPT2 → LIAS (with FDX1/Fe–S support) → LIPT1 → lipoylated PDH/OGDH/BCKDH/GCS (URLs: https://doi.org/10.1016/j.jbc.2023.105046; https://doi.org/10.1177/1073858420936162) (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Cellular processes affected: loss of lipoylation impairs mitochondrial oxidative metabolism, leading to decreased cellular respiration, activation of integrated stress responses, and heightened sensitivity to glucose limitation (URL: https://doi.org/10.1016/j.jbc.2023.105046). Experimental rescue of lipoylation restores basal respiration and proliferation in low glucose (URL: https://doi.org/10.1016/j.jbc.2024.107995) (dreishpoon2023fdx1regulatescellular pages 1-2, bick2024engineeredbacteriallipoate pages 2-3).
- Metabolic consequences: reduced PDH activity promotes pyruvate accumulation and lactic acidosis; reduced OGDH impairs TCA cycle flux (α‑ketoglutarate utilization); reduced BCKDH causes branched‑chain α‑ketoacid accumulation; reduced GCS activity can elevate glycine in some lipoylation disorders. Reviews and case reports link LIPT1 defects to lethal lactic acidosis and Leigh‑like presentations (URL: https://doi.org/10.1177/1073858420936162) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47, kastaniotis2021mitochondrialfattyacids pages 37-42).
- Relationship to copper toxicity (cuproptosis): Lipoylation is central to the copper‑dependent cytotoxic program; upstream regulation by FDX1–LIAS modulates protein lipoylation that participates in copper‑induced cell death signaling. While not a clinical feature of LIPT1 deficiency per se, this mechanistic axis underscores how defective lipoylation alters susceptibility to copper‑linked stress (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).

2) Key Molecular Players
- Genes/Proteins (HGNC):
  - LIPT1 (Lipoyltransferase 1): transfers lipoyl moiety from GCSH to E2 subunits (PDH/OGDH/BCKDH) and maintains lipoylation of the glycine cleavage H‑protein (URLs: https://doi.org/10.1016/j.jbc.2024.107995; https://doi.org/10.1177/1073858420936162) (bick2024engineeredbacteriallipoate pages 4-5, kastaniotis2021mitochondrialfattyacids pages 42-47).
  - LIPT2: octanoyl transfer to GCSH upstream of LIAS (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).
  - LIAS: lipoic acid synthase; inserts sulfur into octanoyl-GCSH; requires Fe–S and is supported by FDX1 (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).
  - FDX1: directly binds LIAS to promote cellular protein lipoylation (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).
  - Upstream mtFAS components (e.g., MECR, ACP/NDUFAB1): provide octanoyl-ACP precursor; deficiency reduces global mitochondrial lipoylation and can impair respiratory complex integrity (URL: https://doi.org/10.1177/1073858420936162) (kastaniotis2021mitochondrialfattyacids pages 42-47).
- Chemical entities (CHEBI): lipoic acid (cofactor); pyruvate; lactate; α‑ketoglutarate; branched‑chain α‑ketoacids (mechanistic relevance inferred via affected complexes) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Cell types (CL): neurons and astrocytes (high oxidative demand); myocytes; hepatocytes—tissues with high mitochondrial flux are vulnerable when lipoylation is impaired (review synthesis) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Anatomical locations (UBERON): central nervous system (brain), skeletal muscle, liver, and heart are commonly implicated in mitochondrial energy failure syndromes and are consistent with reported clinical features in LIPT1 deficiency (review synthesis) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).

3) Biological Processes (GO) Disrupted
- Protein lipoylation; lipoate biosynthetic process; mitochondrial acetyl‑CoA metabolism; pyruvate dehydrogenase complex cycle; tricarboxylic acid (TCA) cycle; branched‑chain amino acid catabolic process; glycine catabolic process; mitochondrial respiratory chain function and cellular respiration (URLs: https://doi.org/10.1016/j.jbc.2023.105046; https://doi.org/10.1177/1073858420936162; https://doi.org/10.1016/j.jbc.2024.107995) (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47, bick2024engineeredbacteriallipoate pages 2-3).

4) Cellular Components
- Mitochondrial matrix (site of PDH/OGDH/BCKDH/GCS and lipoylation reactions); inner mitochondrial membrane/respiratory chain complexes affected secondarily; lipoyl moieties attached to E2 subunits (DLAT, DLST) and GCSH (URLs: https://doi.org/10.1016/j.jbc.2023.105046; https://doi.org/10.1177/1073858420936162; https://doi.org/10.1016/j.jbc.2024.107995) (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47, bick2024engineeredbacteriallipoate pages 2-3).

5) Disease Progression (Mechanistic Sequence)
- Initiation: biallelic pathogenic variants in LIPT1 reduce or abolish transfer of lipoyl groups to E2 subunits/H‑protein.
- Molecular consequences: reduction/absence of lipoylated DLAT/DLST (and likely DBT/GCSH), causing loss of PDH/OGDH/BCKDH/GCS activity and impaired TCA cycle entry and flux (URLs: https://doi.org/10.1016/j.jbc.2024.107995; https://doi.org/10.1177/1073858420936162) (bick2024engineeredbacteriallipoate pages 4-5, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Cellular outcomes: decreased mitochondrial respiration, increased reliance on glycolysis, stress‑response activation, and vulnerability to low‑glucose environments (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).
- Metabolic derangements: pyruvate accumulation and lactic acidosis; α‑ketoglutarate utilization block; branched‑chain α‑ketoacid accumulation; potential glycine elevation depending on GCS involvement (review/case synthesis) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47, kastaniotis2021mitochondrialfattyacids pages 37-42).
- Clinical manifestation: neonatal/infantile onset lactic acidosis; encephalopathy with Leigh‑like features; hypotonia/spasticity; developmental delay; neuroimaging abnormalities (cortical/cerebellar atrophy, white‑matter changes); occasionally systemic features (e.g., congenital sideroblastic anemia reported in one LIPT1‑mutant individual) (URLs: https://doi.org/10.1016/j.jbc.2024.107995; https://doi.org/10.1177/1073858420936162) (bick2024engineeredbacteriallipoate pages 5-6, kastaniotis2021mitochondrialfattyacids pages 37-42).

6) Phenotypic Manifestations (with HP term mapping and links to mechanism)
- Lactic acidosis (HP:0003128): due to reduced PDH activity and impaired entry of pyruvate into the TCA cycle (URL: https://doi.org/10.1177/1073858420936162) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 37-42).
- Developmental delay (HP:0001263) and encephalopathy/Leigh‑like features (HP:0006805/HP:0007340): from global mitochondrial energy failure in CNS (URLs: https://doi.org/10.1177/1073858420936162) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Hypotonia (HP:0001252) and/or spasticity (HP:0001257): neuro‑motor pathway involvement and energy failure (URL: https://doi.org/10.1016/j.jbc.2024.107995) (bick2024engineeredbacteriallipoate pages 5-6).
- Microcephaly (HP:0000252), cortical/cerebellar atrophy (HP:0001272/HP:0001272—cerebellar atrophy), and white‑matter abnormalities (HP:0007340): neuroimaging findings reported across lipoylation‑defect series including LIPT1 (URL: https://doi.org/10.1016/j.jbc.2024.107995) (bick2024engineeredbacteriallipoate pages 5-6).
- Possible elevated glycine (HP:0002150) when GCS is hypolipoylated (supported broadly across lipoylation defects) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Congenital sideroblastic anemia (HP:0004810) as an atypical presentation in a homozygous LIPT1 (p.Ser71Phe) individual (URL: https://doi.org/10.1016/j.jbc.2024.107995) (bick2024engineeredbacteriallipoate pages 4-5, bick2024engineeredbacteriallipoate pages 5-6).

7) Expert Opinions and Analysis (from authoritative sources)
- Mechanistic centrality of FDX1–LIAS: Direct binding between FDX1 and LIAS establishes FDX1 as an upstream regulator of mitochondrial protein lipoylation, separating the phenotype from general Fe–S biogenesis and clarifying the control node upstream of LIPT1 (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).
- Pathway integration of mtFAS and lipoylation: The foundational review emphasizes that mtFAS supplies octanoyl‑ACP for lipoic acid synthesis and that deficits in mtFAS/lipoylation factors (LIAS, LIPT1, LIPT2) lead to multi‑system energy failure, especially in the CNS; it documents lethal lactic acidosis and Leigh‑like disease with LIPT1 defects (URL: https://doi.org/10.1177/1073858420936162) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47, kastaniotis2021mitochondrialfattyacids pages 37-42).
- Therapeutic concept and proof‑of‑principle: A mitochondrially targeted bacterial lipoate protein ligase (lplA) with exogenous lipoic acid can bypass defective human lipoylation biosynthesis and restore lipoylation and respiration in cell models, suggesting a potential route to therapy development (URL: https://doi.org/10.1016/j.jbc.2024.107995) (bick2024engineeredbacteriallipoate pages 2-3, bick2024engineeredbacteriallipoate pages 4-5).

8) Relevant Statistics and Data (recent studies)
- Cellular phenotypes: In human cell models lacking lipoylation (including LIPT1‑mutant cells), basal respiration and proliferation in low glucose are impaired and can be restored by engineered lplA plus lipoic acid (URL: https://doi.org/10.1016/j.jbc.2024.107995) (bick2024engineeredbacteriallipoate pages 2-3).
- Clinical data: Case‑level descriptions note lactic acidosis and severe neurodevelopmental phenotypes in LIPT1 deficiency, including reports of fatal neonatal disease; however, aggregated cohort statistics (e.g., prevalence, survival curves) are not available in the accessible sources cited here (URL: https://doi.org/10.1177/1073858420936162; https://doi.org/10.1016/j.jbc.2024.107995) (kastaniotis2021mitochondrialfattyacids pages 37-42, bick2024engineeredbacteriallipoate pages 5-6).

Embedded Evidence Table
| Source (first author, year, journal) | URL / DOI | Publication date | Key mechanistic findings | Enzymes / complexes affected (PDH/DLAT, OGDH/DLST, BCKDH/DBT, GCS/GCSH) | Pathway context | Clinical / phenotype notes | Context ID to cite |
|---|---|---:|---|---|---|---|---|
| Bick 2024, Journal of Biological Chemistry | https://doi.org/10.1016/j.jbc.2024.107995 | Dec 2024 | Engineered mitochondrial bacterial lplA plus lipoic acid restores protein lipoylation, rescues basal respiration and low‑glucose growth in lipoylation‑deficient cell models; documents a homozygous LIPT1 (c.212C>T, p.Ser71Phe) with reduced lipoylated DLAT/DLST. | PDH / DLAT (explicit); OGDH / DLST (explicit); BCKDH / DBT (not explicit; canonical targets stated); GCS / GCSH (not explicit; canonical targets stated) | mtFAS → LIPT2 → LIAS → LIPT1; LIAS/Fe–S and FDX1 implicated upstream; MLS‑lplA can bypass defective transfer | • Reported patient phenotypes across series: lactic acidosis, developmental delay, hypotonia, spasticity, cortical/cerebellar atrophy; one case with congenital sideroblastic anemia | (bick2024engineeredbacteriallipoate pages 4-5) |
| Dreishpoon 2023, Journal of Biological Chemistry | https://doi.org/10.1016/j.jbc.2023.105046 | Sep 2023 | FDX1 directly binds LIAS and promotes cellular protein lipoylation; FDX1 loss impairs lipoylation‑dependent enzymes causing loss of respiration, integrated stress response, and glucose‑sensitivity; links lipoylation defects to copper‑related toxicity mechanisms. | PDH / DLAT (explicit); OGDH / DLST (explicit); BCKDH / DBT (explicit); GCS / GCSH (explicit) | mtFAS → LIPT2 → LIAS (FDX1 supports LIAS) → LIPT1; emphasizes Fe–S/FDX1 involvement in LIAS activity | • Cellular phenotypes: loss of respiration, sensitivity to mild glucose starvation, induction of stress response | (dreishpoon2023fdx1regulatescellular pages 1-2) |
| Kastaniotis 2021, The Neuroscientist (foundational review) | https://doi.org/10.1177/1073858420936162 | Jul 2021 | mtFAS supplies octanoyl‑ACP precursor for lipoic acid synthesis; mutations in LIPT1 cause a specific lipoylation defect of 2‑ketoacid dehydrogenase complexes leading to mitochondrial energy failure and reported lethal lactic acidosis in cases. | PDH / DLAT (explicit); OGDH / DLST (explicit); BCKDH / DBT (explicit); GCS / GCSH (explicit/inferred) | mtFAS → LIPT2 → LIAS → LIPT1; highlights requirement of Fe–S–dependent LIAS and coordination with Fe–S cluster biogenesis | • Clinical associations: Leigh‑like presentations, fatal neonatal lactic acidosis, dystonia, hypotonia/hypertonia, delayed psychomotor development | (kastaniotis2021mitochondrialfattyacids pages 32-37) |


*Table: Concise evidence table summarizing key mechanistic findings, affected enzyme complexes, pathway context, and clinical notes from three primary/foundational sources on LIPT1 deficiency for rapid reference and knowledge‑base annotation.*

Structured Annotations for Knowledge Base
- Genes/Proteins (HGNC): LIPT1; LIPT2; LIAS; FDX1; DLAT (PDH E2); DLST (OGDH E2); DBT (BCKDH E2); GCSH (GCS H-protein) (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47, bick2024engineeredbacteriallipoate pages 4-5).
- Biological Process (GO-like terms): protein lipoylation; lipoate biosynthetic process; tricarboxylic acid cycle; pyruvate dehydrogenase complex activity; branched‑chain amino acid catabolic process; glycine catabolic process; mitochondrial respiratory chain and cellular respiration (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Cellular Component: mitochondrial matrix; inner mitochondrial membrane/respiratory chain complexes; PDH/OGDH/BCKDH/GCS holoenzymes (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Phenotypes (HP): lactic acidosis (HP:0003128); developmental delay (HP:0001263); hypotonia (HP:0001252); spasticity (HP:0001257); encephalopathy/Leigh‑like features (HP:0006805/HP:0007340); microcephaly (HP:0000252); cortical/cerebellar atrophy (HP:0001272); white‑matter abnormalities (HP:0007340); congenital sideroblastic anemia (HP:0004810) (bick2024engineeredbacteriallipoate pages 5-6, kastaniotis2021mitochondrialfattyacids pages 37-42, kastaniotis2021mitochondrialfattyacids pages 32-37).
- Cell Types (CL): neurons (CL:0000540) and glia; skeletal myocytes (CL:0000187); hepatocytes (CL:0000182) – high energy‑demand tissues implicated in mitochondrial lipoylation defects (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Anatomical Locations (UBERON): brain (UBERON:0000955); skeletal muscle (UBERON:0002385); liver (UBERON:0002107); heart (UBERON:0000948) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).
- Chemical entities (CHEBI): lipoic acid (CHEBI:16497); pyruvate (CHEBI:15361); lactate (CHEBI:16651); α‑ketoglutarate (CHEBI:16810); branched‑chain α‑ketoacids (class) (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47).

Selected Evidence Quotes (verbatim where available)
- “FDX1 regulates protein lipoylation by directly binding to the lipoyl synthase (LIAS) enzyme… [and] the predominant cellular metabolic outcome of FDX1 loss-of-function is manifested through the regulation of the four lipoylation-dependent enzymes ultimately resulting in loss of cellular respiration and sensitivity to mild glucose starvation.” URL: https://doi.org/10.1016/j.jbc.2023.105046 (dreishpoon2023fdx1regulatescellular pages 1-2).
- “Engineered mitochondrial lplA plus lipoic acid… restored protein lipoylation and growth in low glucose… including restoration of lipoylated DLAT and DLST” (paraphrase of results detailed in Bick 2024 JBC). URL: https://doi.org/10.1016/j.jbc.2024.107995 (bick2024engineeredbacteriallipoate pages 2-3, bick2024engineeredbacteriallipoate pages 4-5).
- “Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with a specific lipoylation defect of the 2‑ketoacid dehydrogenase complexes.” (as summarized in the review’s cited case literature). URL: https://doi.org/10.1177/1073858420936162 (kastaniotis2021mitochondrialfattyacids pages 37-42).

Recent Developments and Applications (2023–2024 Priority)
- FDX1–LIAS mechanistic clarification (2023): establishes a direct regulatory interaction controlling mitochondrial protein lipoylation and cellular respiration under glucose limitation; strengthens upstream context for LIPT1‑dependent lipoylation (URL: https://doi.org/10.1016/j.jbc.2023.105046) (dreishpoon2023fdx1regulatescellular pages 1-2).
- Therapeutic concept testing (2024): mitochondrially targeted bacterial lplA plus lipoic acid supplementation rescues lipoylation and respiration in human cell models with lipoylation defects, including LIPT1‑mutant cells, suggesting a tractable therapeutic strategy to bypass endogenous biosynthesis (URL: https://doi.org/10.1016/j.jbc.2024.107995) (bick2024engineeredbacteriallipoate pages 2-3, bick2024engineeredbacteriallipoate pages 4-5).

URLs and Publication Dates
- Dreishpoon MB et al., J Biol Chem. Published Sep 2023. URL: https://doi.org/10.1016/j.jbc.2023.105046 (dreishpoon2023fdx1regulatescellular pages 1-2).
- Bick NR et al., J Biol Chem. Published Dec 2024. URL: https://doi.org/10.1016/j.jbc.2024.107995 (bick2024engineeredbacteriallipoate pages 4-5, bick2024engineeredbacteriallipoate pages 2-3).
- Kastaniotis AJ et al., The Neuroscientist. Published Jul 2021. URL: https://doi.org/10.1177/1073858420936162 (kastaniotis2021mitochondrialfattyacids pages 32-37, kastaniotis2021mitochondrialfattyacids pages 42-47, kastaniotis2021mitochondrialfattyacids pages 37-42).

Limitations and Gaps
- Aggregated clinical statistics (e.g., number of reported families, genotype–phenotype stratification, survival estimates) were not available in the accessible excerpts. The mechanistic picture is strong and consistent, but epidemiology remains to be consolidated from broader clinical genetics literature (bick2024engineeredbacteriallipoate pages 5-6, kastaniotis2021mitochondrialfattyacids pages 37-42).

Conclusion
LIPT1 deficiency is a disorder of mitochondrial protein lipoylation in which failure to transfer the lipoyl cofactor to E2/H‑protein substrates disables PDH, OGDH, BCKDH, and GCS, producing systemic energy failure with hallmark lactic acidosis and neurodevelopmental phenotypes. Upstream mtFAS, LIPT2, and LIAS (supported by FDX1 and Fe–S biogenesis) define a linear pathway culminating in LIPT1‑dependent lipoylation. Recent advances clarify upstream control (FDX1–LIAS) and demonstrate a therapeutic bypass (mitochondrial lplA + lipoic acid) restoring lipoylation and respiration in human cell models, underscoring translational potential (dreishpoon2023fdx1regulatescellular pages 1-2, kastaniotis2021mitochondrialfattyacids pages 42-47, bick2024engineeredbacteriallipoate pages 2-3, bick2024engineeredbacteriallipoate pages 4-5).

References

1. (dreishpoon2023fdx1regulatescellular pages 1-2): Margaret B. Dreishpoon, Nolan R. Bick, Boryana Petrova, Douglas M. Warui, Alison Cameron, Squire J. Booker, Naama Kanarek, Todd R. Golub, and Peter Tsvetkov. Fdx1 regulates cellular protein lipoylation through direct binding to lias. Journal of Biological Chemistry, 299:105046, Sep 2023. URL: https://doi.org/10.1016/j.jbc.2023.105046, doi:10.1016/j.jbc.2023.105046. This article has 169 citations and is from a domain leading peer-reviewed journal.

2. (bick2024engineeredbacteriallipoate pages 4-5): Nolan R. Bick, Margaret B. Dreishpoon, Ava Perry, Anna Rogachevskaya, Sylvia S. Bottomley, Mark D. Fleming, Sarah Ducamp, and Peter Tsvetkov. Engineered bacterial lipoate protein ligase a (lpla) restores lipoylation in cell models of lipoylation deficiency. Journal of Biological Chemistry, 300:107995, Dec 2024. URL: https://doi.org/10.1016/j.jbc.2024.107995, doi:10.1016/j.jbc.2024.107995. This article has 6 citations and is from a domain leading peer-reviewed journal.

3. (kastaniotis2021mitochondrialfattyacids pages 32-37): Alexander J. Kastaniotis, Kaija J. Autio, and Remya R. Nair. Mitochondrial fatty acids and neurodegenerative disorders. The Neuroscientist, 27:143-158, Jul 2021. URL: https://doi.org/10.1177/1073858420936162, doi:10.1177/1073858420936162. This article has 21 citations.

4. (kastaniotis2021mitochondrialfattyacids pages 42-47): Alexander J. Kastaniotis, Kaija J. Autio, and Remya R. Nair. Mitochondrial fatty acids and neurodegenerative disorders. The Neuroscientist, 27:143-158, Jul 2021. URL: https://doi.org/10.1177/1073858420936162, doi:10.1177/1073858420936162. This article has 21 citations.

5. (bick2024engineeredbacteriallipoate pages 2-3): Nolan R. Bick, Margaret B. Dreishpoon, Ava Perry, Anna Rogachevskaya, Sylvia S. Bottomley, Mark D. Fleming, Sarah Ducamp, and Peter Tsvetkov. Engineered bacterial lipoate protein ligase a (lpla) restores lipoylation in cell models of lipoylation deficiency. Journal of Biological Chemistry, 300:107995, Dec 2024. URL: https://doi.org/10.1016/j.jbc.2024.107995, doi:10.1016/j.jbc.2024.107995. This article has 6 citations and is from a domain leading peer-reviewed journal.

6. (bick2024engineeredbacteriallipoate pages 5-6): Nolan R. Bick, Margaret B. Dreishpoon, Ava Perry, Anna Rogachevskaya, Sylvia S. Bottomley, Mark D. Fleming, Sarah Ducamp, and Peter Tsvetkov. Engineered bacterial lipoate protein ligase a (lpla) restores lipoylation in cell models of lipoylation deficiency. Journal of Biological Chemistry, 300:107995, Dec 2024. URL: https://doi.org/10.1016/j.jbc.2024.107995, doi:10.1016/j.jbc.2024.107995. This article has 6 citations and is from a domain leading peer-reviewed journal.

7. (kastaniotis2021mitochondrialfattyacids pages 37-42): Alexander J. Kastaniotis, Kaija J. Autio, and Remya R. Nair. Mitochondrial fatty acids and neurodegenerative disorders. The Neuroscientist, 27:143-158, Jul 2021. URL: https://doi.org/10.1177/1073858420936162, doi:10.1177/1073858420936162. This article has 21 citations.